2025
Gastrointestinal Bleeding in the Older Adult: Pathophysiology, Evaluation, and Management
Sobani Z, Hung K. Gastrointestinal Bleeding in the Older Adult: Pathophysiology, Evaluation, and Management. Current Treatment Options In Gastroenterology 2025, 23: 4. DOI: 10.1007/s11938-025-00469-5.Peer-Reviewed Original ResearchOlder individualsManagement of modifiable risk factorsRisk factorsModifiable risk factorsProportion of individualsOlder AdultsYears of ageBleeding riskGI bleedingManagement of GI bleedingRisk scoreTiming of endoscopic interventionPeri-procedural anticoagulation managementNovel risk scoreComorbid conditionsGastrointestinal (GI) bleedingReduce mortalityHelicobacter pylori infectionMitigate bleeding riskMortalityEndoscopic therapyRiskPrevent rebleedingGastrointestinal bleedingAnticoagulation managementSociodemographic and Systems Risk Factors Associated With Nil by Mouth Noncompliance and Day-of-Procedure Cancellations: A Retrospective Multicenter Case-Control Study.
Goldstein D, Jimenez N, Faulk D, Jones J, Reece-Nguyen T, Gooden C, Markowitz D, Dalal P. Sociodemographic and Systems Risk Factors Associated With Nil by Mouth Noncompliance and Day-of-Procedure Cancellations: A Retrospective Multicenter Case-Control Study. Anesthesia & Analgesia 2025 PMID: 40036165, DOI: 10.1213/ane.0000000000007451.Peer-Reviewed Original ResearchCase-control studySystemic risk factorsRisk factorsNPO guidelinesRetrospective multicenter case-control studyMulticenter retrospective case-control studyRetrospective case-control studyMulticenter case-control studySingle-center studyDay of procedureMultivariate logistic regressionPublic health insuranceYears of ageLanguage of carePediatric patientsMulticenter studyAffected patientsNoncompliance eventsHealth insurance typeIncreased riskMultivariate analysisPrimary outcomeSecondary outcomesElective proceduresHealth insuranceRisk of late sudden death after surgery for congenital heart disease.
Needleman J, Whitehill R, Claxton J, McCracken C, Zmora R, Vinocur J, Oster M, Kochilas L. Risk of late sudden death after surgery for congenital heart disease. Cardiology In The Young 2025, 1-7. PMID: 40012309, DOI: 10.1017/s1047951125000277.Peer-Reviewed Original ResearchCongenital heart diseaseSudden cardiac deathSingle-ventricle physiologyCongenital heart surgerySudden cardiac death riskCardiac deathCardiac death riskHeart surgerySingle-ventricleHeart failurePediatric Cardiac Care Consortium RegistryRisk of late sudden deathLeft-to-right shunt lesionsLeft-to-right shuntCongenital heart disease typeMild congenital heart diseaseHeart diseaseLong-term follow-upDeath riskLate sudden deathGeneral populationCardiac death patientsSudden cardiac death patientsYears of ageMortality ratioThe anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E
Ali M, Stockdale L, Sagara I, Zongo I, Yerbanga R, Mahamar A, Nikièma F, Tapily A, Sompougdou F, Diarra M, Bellamy D, Provstgaard-Morys S, Zoungrana C, Issiaka D, Haro A, Sanogo K, Sienou A, Kaya M, Traore S, Dicko O, Kone Y, Yalcouye H, Thera I, Diarra K, Snell P, Ofori-Anyinam O, Ockenhouse C, Lee C, Ewer K, Tinto H, Djimde A, Ouedraogo J, Dicko A, Chandramohan D, Greenwood B. The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E. Npj Vaccines 2025, 10: 26. PMID: 39915506, PMCID: PMC11802723, DOI: 10.1038/s41541-025-01078-0.Peer-Reviewed Original ResearchDoses of RTS,S/AS01RTS,S/AS01Dose of vaccineBooster dose of vaccineBooster doseAntibody responseCircumsporozoite proteinMalaria-endemic areas of AfricaRTS,S/AS01E malaria vaccineAntibody titresAnti-CSP antibody responsesBurden of malariaMalaria transmission seasonMalaria-endemic areasAnti-CSP antibodiesPlasmodium falciparum sporozoitesRisk of malariaMalaria vaccine RTS,S/AS01Incidence of malariaAssociated with protectionMultiplex assayYears of ageSevere malariaMalaria vaccineS/AS01Sex differences in in-hospital outcomes and readmission rates after percutaneous coronary intervention
Gomez J, Park D, Eder M, An S, Lowenstern A, Kelsey M, Rymer J, Douglas P, Nanna M. Sex differences in in-hospital outcomes and readmission rates after percutaneous coronary intervention. Baylor University Medical Center Proceedings 2025, 38: 159-169. PMID: 39990004, PMCID: PMC11845020, DOI: 10.1080/08998280.2025.2452113.Peer-Reviewed Original ResearchIn-hospital outcomesIn-hospital mortalitySecondary outcomesReadmission ratesOdds of in-hospital mortalityPercutaneous coronary interventionCalculate odds ratiosInpatient percutaneous coronary interventionHazard of readmissionUnited States National Readmission DatabaseIn-hospital adverse outcomesPropensity score matchingHealth systemHospital characteristicsOdds of cardiac arrestSocioeconomic statusReimbursement implicationsSex differencesYears of ageOdds ratioReadmission riskCox proportional-hazardsLogistic regressionIn-hospital complicationsScore matchingP-567. Baseline Patient and Clinician Results for the Pilot Project I-CARE-4-PAH (Intervention for Collaborative Care to Assess Risk and Eliminate polyPharmacy, Falls, and Fragility Fractures for People Aging with HIV)
Womack J, Johnson C, Danvers K, Hsieh E, Lauro M, Marottoli R, Murphy A, Payne E, Sheehan L, Stewart W, Virata M, Barakat L. P-567. Baseline Patient and Clinician Results for the Pilot Project I-CARE-4-PAH (Intervention for Collaborative Care to Assess Risk and Eliminate polyPharmacy, Falls, and Fragility Fractures for People Aging with HIV). Open Forum Infectious Diseases 2025, 12: ofae631.765. PMCID: PMC11777831, DOI: 10.1093/ofid/ofae631.765.Peer-Reviewed Original ResearchMedication reconciliationHIV cliniciansYears of ageHIV primary careIntersecting risk factorsAcademic HIV clinicPre-test assessmentPeripheral neuropathyClinician championsFall preventionPrimary careHealthcare providersIdentified polypharmacySmoking tobaccoAssociated with ageHIV clinicFRAX scorePlantar surfaceFragility fracturesQuarter of patientsRisk factorsDecreased sensationFracture riskHIVTraining resourcesP-1280. Vaccinating Your Child During an Emergency Is More Important Than Ever: A Randomized Controlled Trial on Message Framing Among Ukrainian Refugees in Poland
Kleszczewska D, Sochoń-Latuszek A, Winters M, Lewtak K, Nurzhynska A, Yoruk K, Kukuła K, Bahruddinov M, Kusek A, Dzielska A, Maciejewski T, Mazur J, Melchinger H, Kinsman J, Christie S, Omer S. P-1280. Vaccinating Your Child During an Emergency Is More Important Than Ever: A Randomized Controlled Trial on Message Framing Among Ukrainian Refugees in Poland. Open Forum Infectious Diseases 2025, 12: ofae631.1461. PMCID: PMC11777220, DOI: 10.1093/ofid/ofae631.1461.Peer-Reviewed Original ResearchRandomized controlled trialsIntervention groupVaccination appointmentsPolish healthcare systemVaccine informationHealth workersIntervention messagesControl groupHealthcare systemRandomized to 1Years of ageInclusion criteriaRefugee mothersControlled trialsPrimary outcomeIncreased intentionVaccination intentionAppointmentUkrainian refugeesVaccination coverageMothersInterventionUkrainian mothersRiskChildrenImpact of patient age on morbidity and mortality in adults with acute traumatic cervical spinal cord injury: An ACS trauma quality programs database study
Elsamadicy A, Serrato P, Belkasim S, Ghanekar S, Khalid S, Lo S, Sciubba D. Impact of patient age on morbidity and mortality in adults with acute traumatic cervical spinal cord injury: An ACS trauma quality programs database study. Clinical Neurology And Neurosurgery 2025, 249: 108740. PMID: 39813756, DOI: 10.1016/j.clineuro.2025.108740.Peer-Reviewed Original ResearchConceptsIn-hospital mortalityAcute CSCI patientsLength of stayCSCI patientsTreatment modalitiesCervical SCIAcute traumatic cervical spinal cord injuryTraumatic cervical spinal cord injuryAssociated with increased morbidityImpact of patient ageAcute cervical SCICervical spinal cord injuryRetrospective cohort studyMultivariate logistic regressionPredictors of AEYears of ageSpinal cord injuryCervicothoracic fusionAssociated with AECervical fusionPatient ageIndependent predictorsInjury typePatient demographicsProgram databaseA comprehensive analysis of serotype-specific invasive capacity, clinical presentations, and mortality trends of invasive pneumococcal disease
Yildirim M, Keskinocak P, Hinderstein S, Tran K, Dasthagirisaheb Y, Madoff L, Pelton S, Yildirim I. A comprehensive analysis of serotype-specific invasive capacity, clinical presentations, and mortality trends of invasive pneumococcal disease. Vaccine 2025, 47: 126692. PMID: 39778476, DOI: 10.1016/j.vaccine.2024.126692.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseasePneumococcal conjugate vaccineClinical presentationInvasive diseasePneumococcal diseaseAnnual incidence of invasive pneumococcal diseaseIncidence of invasive pneumococcal diseaseInvasive capacityInvasive pneumococcal disease serotypesPost-PCV13 eraReduced invasive diseasePneumococcal nasopharyngeal colonizationYears of ageNP carriageSerotype 35BPost-PCV13Respiratory seasonsCarriage prevalenceNasopharyngeal colonizationStreptococcus pneumoniaeConjugate vaccineSerotype 18CAnnual incidenceVaccination strategiesNP isolatesThe Interplay Between Respiratory Syncytial Virus and Asthma Inception: Insights Gained From the COVID‐19 Pandemic
Amram T, Duek O, Golan‐Tripto I, Goldbart A, Greenberg D, Hazan G. The Interplay Between Respiratory Syncytial Virus and Asthma Inception: Insights Gained From the COVID‐19 Pandemic. Pediatric Pulmonology 2025, 60: e27474. PMID: 39760467, PMCID: PMC11748096, DOI: 10.1002/ppul.27474.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusYears of ageSyncytial virusRespiratory syncytial virus bronchiolitisRespiratory syncytial virus infectionRespiratory syncytial virus exposureRSV-induced inflammationRespiratory syncytial virus activityMultivariate logistic regressionAirway changesAsthma inceptionRetrospective studyAsthma surrogateIncreased riskLogistic regressionAsthmaCause of asthmaCOVID-19 pandemicHealthcare organizationsPredispositionIncreased rateChildrenCOVID-19AgeVirus
2024
Pancreaticoduodenectomy in trauma patients with grade IV–V duodenal or pancreatic injuries: a post hoc analysis of an EAST multicenter trial
Choron R, Piplani C, Kuzinar J, Teichman A, Bargoud C, Sciarretta J, Smith R, Hanos D, Afif I, Beard J, Dhillon N, Zhang A, Ghneim M, Devasahayam R, Gunter O, Smith A, Sun B, Cao C, Reynolds J, Hilt L, Holena D, Chang G, Jonikas M, Echeverria-Rosario K, Fung N, Anderson A, Fitzgerald C, Dumas R, Levin J, Trankiem C, Yoon J, Blank J, Hazelton J, McLaughlin C, Al-Aref R, Kirsch J, Howard D, Scantling D, Dellonte K, Vella M, Hopkins B, Shell C, Udekwu P, Wong E, Joseph B, Lieberman H, Ramsey W, Stewart C, Alvarez C, Berne J, Nahmias J, Puente I, Patton J, Rakitin I, Perea L, Pulido O, Ahmed H, Keating J, Kodadek L, Wade J, Henry R, Schreiber M, Benjamin A, Khan A, Mann L, Mentzer C, Mousafeiris V, Mulita F, Reid-Gruner S, Sais E, Foote C, Palacio C, Argandykov D, Kaafarani H, Manderski M, Moko L, Narayan M, Seamon M. Pancreaticoduodenectomy in trauma patients with grade IV–V duodenal or pancreatic injuries: a post hoc analysis of an EAST multicenter trial. Trauma Surgery & Acute Care Open 2024, 9: e001438. PMID: 39717488, PMCID: PMC11664373, DOI: 10.1136/tsaco-2024-001438.Peer-Reviewed Original ResearchLonger intensive care unit length of stayGrade IV-VBlood product requirementsNon-PD patientsGI complicationsPancreatic injuryPD patientsMulticenter retrospective comparative studyLonger intensive care unit lengthAmerican Association for the SurgeryNon-PDIntensive care unit length of stayGrade VUnit length of stayMultivariate logistic regression analysisIV-VPancreatic ductal injuryProcedure-related morbiditySubanalysis of patientsRetrospective comparative studyLevel 1 trauma centerNon-PD groupLogistic regression analysisYears of agePost hoc analysisStreptococcus pneumoniae Serotype Distribution Among US Adults Hospitalized With Community-Acquired Pneumonia, 2019–2020
Ramirez J, Hubler R, Ali M, Gray S, Carrico R, McNaughton C, Wunderink R, Dela Cruz C, Chilson E, Cané A, Isturiz R, Pride M, Jodar L, Gessner B, Grant L. Streptococcus pneumoniae Serotype Distribution Among US Adults Hospitalized With Community-Acquired Pneumonia, 2019–2020. Open Forum Infectious Diseases 2024, 12: ofae727. PMID: 39758745, PMCID: PMC11697090, DOI: 10.1093/ofid/ofae727.Peer-Reviewed Original ResearchCommunity-acquired pneumoniaPneumococcal conjugate vaccineStreptococcus pneumoniae</i>Urinary antigen detectionSerotype-specific urinary antigen detectionStreptococcus pneumoniae serotypes distributionUrinary antigen detection assayPneumococcal community-acquired pneumoniaAdult community-acquired pneumoniaRadiographic evidence of community-acquired pneumoniaHigher-valent pneumococcal conjugate vaccinesMedical chart reviewYears of ageCommunity-acquiredSerotype distributionRespiratory samplesChart reviewConjugate vaccineSerotype pneumococciPer-protocolChronic medical conditionsRadiographic evidenceAntigen detectionCoronavirus disease 2019Proportion of adultsA Substantial Increase in Injuries and Hospitalizations Associated with Playing Pickleball from 2020 to 2022: A National Database Study
Cheng R, Moran J, Kim B, Yuan M, O’Leary C, Wang C, Dines J, Katt B, Jimenez A. A Substantial Increase in Injuries and Hospitalizations Associated with Playing Pickleball from 2020 to 2022: A National Database Study. Arthroscopy Sports Medicine And Rehabilitation 2024, 101067. DOI: 10.1016/j.asmr.2024.101067.Peer-Reviewed Original ResearchNational Electronic Injury Surveillance SystemU.S. emergency departmentsEmergency departmentHospital admissionNEISS databaseElectronic Injury Surveillance SystemInjury Surveillance SystemEmergency department visitsIncreased riskTime of injuryNational database studyDepartment visitsInjury typeYears of ageMultivariate analysisSurveillance systemHospitalDatabase studyPlaying pickleballAdmissionDepartmentCategorize injuriesSite of injuryRiskUnited StatesIdentifying diagnosed major chronic diseases associated with recent housing instability among aging adults: data from the ‘All of Us’ research program
Beydoun H, Vieytes C, Beydoun M, Lampros A, Tsai J. Identifying diagnosed major chronic diseases associated with recent housing instability among aging adults: data from the ‘All of Us’ research program. Journal Of Public Health 2024, 47: 15-23. PMID: 39586798, DOI: 10.1093/pubmed/fdae300.Peer-Reviewed Original ResearchUs Research ProgramHousing instabilityAging adultsChronic diseasesOdds ratioChronic disease preventionAssociated with lower oddsPsychiatric diagnosisConfidence intervalsElectronic health recordsAssociated with psychiatric diagnosesEstimate odds ratiosCardiovascular diseaseMultivariate logistic regression modelDiverse group of adultsLogistic regression modelsTreatment of chronic diseasesCross-sectional dataHealth recordsHealthcare utilizationLower oddsGroup of adultsYears of ageDiagnosed diabetesCancer diagnosisWorldwide Clinical and Real-World Exposure to Baricitinib
Vleugels R, Craiglow B, Mostaghimi A, Olsen E, Sontag A, Denning K, Somani N, Hordinsky M. Worldwide Clinical and Real-World Exposure to Baricitinib. SKIN The Journal Of Cutaneous Medicine 2024, 8: s501. DOI: 10.25251/skin.8.supp.501.Peer-Reviewed Original ResearchLength of therapyClinical trialsAtopic dermatitisTreated with baricitinibAverage length of therapyAge 2 yearsJuvenile idiopathic arthritisYears of ageMonths of ageBaricitinib doseAverage daily doseYrs of agePediatric patientsAcute infectious diseaseDaily doseCOVID-19 infectionAlopecia areataJAK inhibitorsHospitalized patientsIdiopathic arthritisBaricitinibPatientsBlind trialRheumatoid arthritisDisease statesSpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial
Merola J, Strober B, Gottlieb A, Mostaghimi A, Hawkes J, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients switching from conventional systemic treatments: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s488. DOI: 10.25251/skin.8.supp.488.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementSystemic medicationsConventional systemic treatmentsAverage body surface areaTreating generalized pustular psoriasisLife-threatening skin diseaseSignificant patient burdenYears of ageSystemic therapyDosing regimenSystemic treatmentPediatric patientsPustular psoriasisExtent of involvementSpesolimabWeek 4Skin symptomsPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremitySpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial
Mostaghimi A, Strober B, Merola J, Gottlieb A, Elewski B, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time in patients with various lengths of disease history: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s489. DOI: 10.25251/skin.8.supp.489.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementWeek 4Disease historyAverage body surface areaTreating generalized pustular psoriasisYear prior to enrollmentLife-threatening skin diseaseSignificant patient burdenYears of ageDosing regimenPediatric patientsPustular psoriasisExtent of involvementSpesolimabDisease courseSkin symptomsPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremityTime pointsSpesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial
Gottlieb A, Strober B, Merola J, Mostaghimi A, Farberg A, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab increases the percentage of generalized pustular psoriasis (GPP) patients with clear skin over time as measured by the Physician’s Global Assessment for GPP (GPPGA): Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s490. DOI: 10.25251/skin.8.supp.490.Peer-Reviewed Original ResearchGeneralized pustular psoriasisPhysician global assessmentSkin symptomsPustular psoriasisGlobal assessmentProportion of patientsPercentage of patientsTreating generalized pustular psoriasisLife-threatening skin diseaseSignificant patient burdenYears of ageDosing regimenPediatric patientsClear skinSpesolimabPatientsContinuous treatmentMonoclonal antibodiesSkin diseasesPatient burdenSymptomsPsoriasisTotal scoreSkinTreatmentSpesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time: Results from the EFFISAYIL® 2 trial
Strober B, Merola J, Gottlieb A, Mostaghimi A, Hsiao J, Guercio J, Tang M, Thoma C, Lebwohl M. Spesolimab decreases generalized pustular psoriasis (GPP) body surface area (BSA) over time: Results from the EFFISAYIL® 2 trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s491. DOI: 10.25251/skin.8.supp.491.Peer-Reviewed Original ResearchGeneralized pustular psoriasisBody surface areaBody surface area involvementTreating generalized pustular psoriasisLife-threatening skin diseaseArea of involvementSignificant patient burdenYears of ageDosing regimenPediatric patientsPustular psoriasisExtent of involvementSpesolimabSkin symptomsContinuous treatmentPatientsMonoclonal antibodiesLower extremitiesSkin diseasesPatient burdenUpper extremityTime pointsTreatmentInvolvementBody regionsSerum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade
Najarro G, Gupta V, Joseph N, Kaufman J, Nooka A, Dhodapkar M, Lonial S, Hofmeister C. Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade. Blood 2024, 144: 5142-5142. DOI: 10.1182/blood-2024-202078.Peer-Reviewed Original ResearchFree light chain ratioLight chain ratioSerum free light chain ratioSerum free light chainsFLC ratioFree light chainsFreelite assayChain ratioCKD-EPIHistory of lymphoproliferative disordersThermo FisherLight chainPeriod of 6-monthsMedian valueYears of agePlasma cell productionLymphoproliferative disordersAlpha 1-antitrypsinPrevent MMHealthy donorsLymphoproliferative diseaseBlood testsRenal clearanceSerum concentrationsEGFR
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply